Staying Ahead of Resistance: Multi-Treated Breast Cancer
November 6, 2025
Patient: 52 years – Female with recurrent metastatic breast carcinoma (ER+, HER2–) Clinical Testing:Alterations: ESR1 (mutation), PIK3CA (VUS)Genes: ESR1, PIK3CATreatment Options: Sequential use of